{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:56Z","timestamp":1790704376805,"version":"4.1.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) serves as a promising medicine, with few known adverse effects apart from the potential of drug interactions with the cytochrome P450 system. It has been hypothesized drug interactions may occur with chemotherapeutic agents, but no supporting evidence has been published to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case:<\/jats:title>\n                    <jats:p>A 58-year-old female with a history of bilateral breast carcinoma in remission, was treated with tamoxifen for breast cancer prevention for over 6 years. CBD was instituted to treat persistent postsurgical pain, inadequately managed by alternate analgesics. It was postulated that CBD may diminish tamoxifen metabolism by CYP3A4 and 2D6 to form active metabolite endoxifen, which exerts the anticancer benefits. Endoxifen, tamoxifen, N-desmetyltamoxifen and 4-hydroxytamoxifen levels were collected while the patient chronically received CBD 40 mg\/day, and after a 60-day washout. Upon discontinuation of CBD 40 mg\/day, it was observed that endoxifen levels increased by 18.75% and N-desmethyltamoxifen by 9.24%, while 4-hydroxytamoxifen remained unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CBD at a low dose of 40 mg\/day resulted in the potential inhibition of CYP3A4 and\/or CYP2D6. Patients receiving CBD and interacting chemotherapeutic drugs, such as tamoxifen, require monitoring to identify possible subtherapeutic response to treatment. Further pharmacokinetic studies are required to ascertain the dynamics of this drug interaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190020972208","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T01:17:41Z","timestamp":1605489461000},"page":"322-326","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction"],"prefix":"10.1177","volume":"35","author":[{"given":"Vikas","family":"Parihar","sequence":"first","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"},{"name":"Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Rogers","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Marie","family":"Blain","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"},{"name":"Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Ramesh Kumar","family":"Zacharias","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"},{"name":"Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Laureen","family":"Patterson","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Abdel-Magid","family":"Siyam","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote Pain Clinic, McMaster University Medical Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,11,15]]},"reference":[{"key":"bibr1-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000779"},{"key":"bibr2-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2017.07.002"},{"key":"bibr3-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000364"},{"key":"bibr4-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019828920"},{"key":"bibr5-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2014.03.007"},{"key":"bibr6-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.02.017"},{"key":"bibr7-0897190020972208","unstructured":"GW Biosciences. Epidiolex (cannabidiol) oral solution. [Full Prescribing Information]. U.S. Food and Drug Administration website. Updated June 2018. Accessed July 16, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"},{"key":"bibr8-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2015.07.007"},{"key":"bibr9-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041384"},{"key":"bibr10-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90357-8"},{"key":"bibr11-0897190020972208","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-14-RG-014"},{"key":"bibr12-0897190020972208","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"bibr13-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665"},{"key":"bibr14-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr15-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.32"},{"key":"bibr16-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714631"},{"key":"bibr17-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00379-8"},{"key":"bibr18-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005254"},{"key":"bibr19-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611618"},{"key":"bibr20-0897190020972208","first-page":"6091","volume":"2","author":"Lewis MM","year":"2017","journal-title":"Am Chem Soc Omega"},{"key":"bibr21-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1080\/03602530902843483"},{"key":"bibr22-0897190020972208","doi-asserted-by":"crossref","unstructured":"Xu C, Ogburn ET, Guo Y.Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos. 2012;40(4):717\u2013725. Updated April 1, 2012. Accessed July 16, 2019. http:\/\/dmd.aspetjournals.org\/content\/40\/4\/717.","DOI":"10.1124\/dmd.111.042416"},{"key":"bibr23-0897190020972208","unstructured":"Ellingrod L, Skaar TC, M\u00fcller DJ, et al. Supplement to: clinical pharmacogenetics implementation consortium guideline for. 2017;49(0):1\u201320."},{"key":"bibr24-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209377"},{"key":"bibr25-0897190020972208","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.314"},{"key":"bibr26-0897190020972208","unstructured":"AstraZeneca Pharmaceuticals. Iressa (Gefitinib). [Product Monograph]. AstraZeneca Canada Incorporated product information website. Published 2015. Updated September 27, 2017. Accessed July 16, 2019. https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/iressa-product-monograph-en.pdf."},{"key":"bibr27-0897190020972208","doi-asserted-by":"crossref","unstructured":"Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998;18(6):1304\u20131307. Updated January 17, 2012. Accessed July 16, 2019. https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/j.1875-9114.1998.tb03152.x","DOI":"10.1002\/j.1875-9114.1998.tb03152.x"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020972208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190020972208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190020972208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:23Z","timestamp":1777509383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190020972208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/0897190020972208"],"URL":"https:\/\/doi.org\/10.1177\/0897190020972208","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,15]]}}}